Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (1) · (multiple, generic dominant) (1) · Vistaril (pamoate), Atarax (HCl, discontinued in US as brand) (1)

Analgesic (2) · Opioid (2) · Prodrug (1) · [[:Category:Antihistamines|First-generation antihistamine]] (1) · [[:Category:Antipruritics|Antipruritic]] (1) · [[:Category:Anxiolytics|Anxiolytic]] (1) · [[:Category:Sleep aids|Sleep aid (off-label)]] (1)

Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · '"`UNIQ--vote-0000001D-QINU`"' '''QT prolongation''' risk at high doses prompted the FDA's 2015 caution against use in patients with prolonged QT or with concurrent QT-prolonging medicines'"`UNIQ--ref-0000001E-QINU`"'. (1)

None (1) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (1)

None (1) · Adult: 15–60 mg every 4 hours as needed. (1) · Anxiety: 25-50 mg PO QID. Pruritus: 25 mg PO TID-QID. Insomnia: 25-50 mg PO at bedtime. Pediatric: 50-100 mg/day divided (1)

None (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1) · Tablets 10, 25, 50 mg (HCl); capsules 25, 50, 100 mg (pamoate); oral suspension 25 mg/5 mL; injection 25, 50 mg/mL (IM only, never IV) (1)

None (1) · 360 mg/day (1) · 400 mg/day theoretical; in practice rarely exceeds 200 mg/day (1)

None (1) · intramuscular (1) · Oral (1) · PO (only formulation marketed in the US). (1)

None (1) · 15-30 minutes (oral) (1) · 30–60 min (PO) (1)

None (1) · 4-6 hours (1) · 4–6 hours (1)

None (1) · 14-25 hours (longer in elderly and hepatic impairment)'"`UNIQ--ref-00000026-QINU`"' (1) · 2.5–3 hours (1)

None (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~80% (oral)'"`UNIQ--ref-00000027-QINU`"' (1)

None (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited human data; older agent with substantial use experience; some signal for first-trimester exposure but not conclusive.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, which is a meaningful clinical advantage over the benzodiazepine alternatives for short-term anxiety'"`UNIQ--ref-00000028-QINU`"' (1)